ArticleJournal of family medicine and primary care2025
Effective use of saline-diluted subcutaneous glargine in very low birth weight babies with neonatal hyperglycemia.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case series documents two very low birth weight neonates who presented with spontaneous hyperglycemia even after discontinuation of steroids in a critical care setting. Despite attempts to regulate their glucose levels using intravenous insulin infusion as per standard protocol, we faced challenges with dosage adjustment and observed significant fluctuations in their blood sugar levels requiring frequent glycemic monitoring (every 2 hours). As hyperglycemia continued, we decided to switch to the subcutaneous route of administration and reduce the frequency of glycemic monitoring. However, due to weight-based insulin dose calculation, a very low insulin dose had to be administered necessitating insulin dilution. Due to unavailability of commercial diluents, we explored saline as a diluent for glargine based on acidic pH similarity between glargine and saline. We observed that the saline-diluted glargine administered subcutaneously was effective in managing hyperglycemia, and their blood glucose levels stabilized within the desired range requiring less frequent monitoring (every 6 hours).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.